Phase 4 Trial Finds Tudorza Safe and Effective for COPD Patients with Cardiovascular Disease
Long-term use of Tudorza (aclidinium bromide) can significantly and safely reduce exacerbations in people with moderate to severe chronic obstructive pulmonary disease and cardiovascular disease or risk factors, findings in a Phase 4 post-marketing study show. Tudorza, developed by AstraZeneca, contains the long-acting muscarinic antagonist (LAMA) aclidinium bromide,…